Revenio Group Corporation, Stock Exchange Release, July 1, 2015 at 9:00
Icare enters into distribution cooperation with Topcon Medical in the US
Revenio Group Corporation's subsidiary Icare Finland Plc has signed a distribution agreement with Topcon Medical Systems (TMS), the US subsidiary of Topcon Corporation (Tokyo, Japan). According to the agreement, TMS will act as the sole distributor of Icare products to ten of the largest optical chains in the United States. Topcon is known worldwide as a leading manufacturer of ophthalmic devices.
TMS has an extensive sales network in the US and has developed long-term relationships with several of the largest optical chains.
"I am extremely pleased with the now undersigned distribution agreement. Topcon has a very strong position in the US optical chains, which opens us up a significant new sales channel. These ten large optical chains that are under the agreement cover most of the optical shops in the United States. With the undersigned distribution agreement we strengthen our growth opportunities in the US marketplace," states Timo Hildén, CEO, Icare Finland Plc.
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
Topcon Medical Systems Inc in brief
Topcon Medical Systems Inc is wholly owned subsidiary of Topcon Corporation (Tokyo, Japan). Topcon is a Tokyo Stock Exchange listed company, established in 1934. Topcon's net sales in 2014 totaled to 128,569 million yen. Topcon's in-house companies are segmented into three business units, Positioning, Smart Infrastructure and Eye Care. For more information on Topcon, please visit: www.topcon.com
The Revenio Group in brief
Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specialize in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki. www.revenio.fi